Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Atrial fibrillation? 57 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 57 reports of Atrial fibrillation have been filed in association with BASILIXIMAB (Simulect). This represents 0.8% of all adverse event reports for BASILIXIMAB.

57
Reports of Atrial fibrillation with BASILIXIMAB
0.8%
of all BASILIXIMAB reports
31
Deaths
43
Hospitalizations

How Dangerous Is Atrial fibrillation From BASILIXIMAB?

Of the 57 reports, 31 (54.4%) resulted in death, 43 (75.4%) required hospitalization, and 29 (50.9%) were considered life-threatening.

Is Atrial fibrillation Listed in the Official Label?

Yes, Atrial fibrillation is listed as a known adverse reaction in the official FDA drug label for BASILIXIMAB.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Off label use (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298)

What Other Drugs Cause Atrial fibrillation?

APIXABAN (5,690) IBRUTINIB (3,671) LENALIDOMIDE (2,704) RITUXIMAB (2,100) SACUBITRIL\VALSARTAN (2,062) RIVAROXABAN (2,027) ADALIMUMAB (1,709) METOPROLOL (1,462) DEXAMETHASONE (1,461) METHOTREXATE (1,411)

Which BASILIXIMAB Alternatives Have Lower Atrial fibrillation Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Atrial fibrillation Reports All Drugs Causing Atrial fibrillation BASILIXIMAB Demographics